Abstract
Summary. Aim:to evaluate the immediate treatment outcomes and overall and relapse-free survival of patients with ovarian cancer stage III-IV depending on the treatment method. Object and methods: the study presents the overall and relapse-free survival results of 269 patients with ovarian cancer stage III-IV who received comprehensive treatment at the “Prykarpattia Clinical Oncology Center of the Ivano-Frankivsk Regional Council” between 2017 and 2023. Patients were divided into 3 groups based on the treatment method: Group I – primary cytoreductive surgery followed by 6 adjuvant cycles of polychemotherapy (PCT); Group II – three neoadjuvant cycles of PCT, interval cytoreductive surgery, and adjuvant PCT; Group III – 6 cycles of PCT. All patients received chemotherapy following the paclitaxel-carboplatin regimen. Results: in all groups, 19 (7%) cases of platinum-resistant ovarian cancer were identified, and the treatment outcomes for these patients were not included in survival calculations. The 3-year overall cumulative survival rate was 50% in group I, 58% in group II, and 36% in group III. The median overall survival in group I was 31 months, in group II – 37 months, and in group III – 17 months. The 3-year relapse-free cumulative survival was 24% in group I, 48% in group II, and 36% in group III. The median relapse-free survival in group I was 19 months, in group II – 25 months, and in group III – 17 months. Conclusions: relapse-free and overall survival rates were significantly better in patients who received comprehensive treatment compared to those who only underwent chemotherapy cycles. The use of neoadjuvant chemotherapy in patients with stage III-IV ovarian cancer improves relapse-free survival but does not affect overall survival compared to patients who underwent primary cytoreductive surgery.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call